Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-β signaling in ErbB2/Neu-induced tumors from transgenic mice
Authors:
Open Access
- 9 May 2005
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 24 (33) , 5173-5190
Abstract
Upregulation of HER2/ErbB2/Neu occurs in 15–30% of human breast cancers and correlates with poor prognosis. Identification of ErbB2/Neu transcriptional targets should facilitate development of novel therapeutic approaches. Development of breast cancer is a multistep process; thus, to identify the transcriptomes associated with different stages of progression of tumorigenesis, we compared expression profiles of mammary tumors and preneoplastic mammary tissue from MMTV-Neu transgenic mice to expression profiles of wild-type mammary glands using Affymetrix microarrays. We identified 324 candidate genes that were unique to ErbB2/Neu-induced tumors relative to normal mammary gland tissue from wild-type controls. Expression of a subset of these genes (82) was also changed in the preneoplastic mammary glands compared to wild-type controls, indicating that they may play a pivotal role during early events of ErbB2/Neu-initiated mammary tumorigenesis. Further analysis of the microarray data revealed that expression of several known transforming growth factor (TGF)-β target genes was altered, suggesting that the TGF-β signaling cascade is downregulated in ErbB2/Neu-induced tumors. Western blot analysis for TGF-β-Receptor-I/ALK5 and immunohistochemistry for TGF-β-Receptor-I/ALK5 and phosphorylated/activated Smad2 confirmed that the Smad-dependent TGF-β signaling cascade was inactive in these tumors. Although absent in most of the tumor, phosphorylated Smad2 was present in the periphery of tumors. Interestingly, presence of phosphorylated/activated Smad2 correlated with expression of Activin-Receptor-IB/ALK4, suggesting that although Smad-dependent TGF-β signaling is absent in ErbB2/Neu-induced tumors, Activin signaling may be active at the leading edge of these tumors. Cumulatively, these data indicate that the TGF-β pathway is intrinsically suppressed in ErbB2/Neu tumors via a mechanism involving loss of TGF-β-Receptor-I/ALK5.Keywords
This publication has 58 references indexed in Scilit:
- Identification and validation of an ERBB2 gene expression signature in breast cancersOncogene, 2004
- Expression of an engrailed-LMO4 fusion protein in mammary epithelial cells inhibits mammary gland development in miceOncogene, 2003
- HER2/Neu- and TAK1-mediated Up-regulation of the Transforming Growth Factor β Inhibitor Smad7 via the ETS Protein ER81Journal of Biological Chemistry, 2003
- The ErbB receptors and their role in cancer progressionExperimental Cell Research, 2003
- A molecular signature of metastasis in primary solid tumorsNature Genetics, 2002
- Autocrine Regulation of Myocyte Cx43 Expression by VEGFCirculation Research, 2002
- ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalingThe EMBO Journal, 1997
- Activated neu Induces Rapid Tumor ProgressionJournal of Biological Chemistry, 1996
- The biology of erbB-2/nue/HER-2 and its role in cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1994
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989